A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Inclusion Criteria: * Male and female subjects ages \>18 years of age, inclusive. * History of plasma TG concentration ≥890 mg/dl (10 mmol/L) or history of lactescent plasma in the fasting state. * Fasting TG ≥ 750 mg/dL (8.5 mmol/L) at day -7 or repeat of day -7 one week later for those failing to qualify initially and thought likely to qualify on repeat examination prior to randomization. Exclusion Criteria: * Treatment with Omega-3 fatty acids or niacin or fibrates within 8 weeks of screening. * Patients with confirmed Familial Chylomicronemia Syndrome (FCS) with hyperlipoproteinemia (HLP) Type-I diagnosis or known to be homozygotes or compound heterozygotes for mutations in HLP Type I-causing genes (such as LPL, apoCII, CPIHBP1, or LMF1) prior to screening. * Pancreatitis within 3 months prior to screening. * Uncontrolled type 2 diabetes (T2DM) (as defined by an HbA1c value of ≥8.0% at screening) * BMI \> 40 or history of bariatric surgery. * Nephrotic syndrome, Type 1 diabetes, HIV, HCV or HBV positive. * Estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min/1.73m2 Other protocol defined inclusion/exclusion criteria may apply